# 2025年12月15日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 靶向 m6A 去甲基化酶 ALKBH5 可抑制结直肠癌的干性与化疗耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390849)
**期刊：** Nature communications
**PMID：** 41390849
**DOI：** 10.1038/s41467-025-67502-0

### 第一部分 原文与翻译

**英文原标题：** Targeting of the mA eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer.

> **英文摘要：**
> The role of RNA N-methyladenoine (mA) eraser AlkB homologue 5 (ALKBH5) in colorectal cancer (CRC) stem cells (CSCs) is unclear. Here, we find that ALKBH5 expression positively correlates with CSC markers in CRC patients. ALKBH5 induces self-renewal and stemness markers in colorectal CSCs and patient-derived organoids (PDOs). Colon-stem cell specific Alkbh5 knockin accelerates carcinogen-induced CRC, while tumorigenesis is attenuated in colon-stem cell specific Alkbh5 knockout mice. Integrated RNA-seq, MeRIP-seq and Ribo-seq reveal FAM84A as an ALKBH5 target. ALKBH5 demethylates mA-modified FAM84A mRNA, causing mRNA decay and reduced expression. Mechanistically, we show that FAM84A represses CSCs by interacting with β-catenin and promoting β-catenin ubiquitination and degradation. By boosting CSCs, ALKBH5 overexpression elicit chemoresistance in CSCs, PDOs and transgenic mice. Targeting of ALKBH5 by knockout or VNPs-siALKBH5 synergizes with chemotherapy to trigger tumor regression in CSCs-/PDOs-derived xenografts and ALKBH5 knockout mice. Together, we reveal that ALKBH5 is essential for colorectal CSCs and is a therapeutic target for overcoming CRC chemoresistance.

> **中文摘要：**
> RNA N-甲基腺苷（m6A）去甲基化酶 AlkB 同源物 5（ALKBH5）在结直肠癌（CRC）干细胞（CSCs）中的作用尚不清楚。本研究发现，在 CRC 患者中，ALKBH5 的表达水平与 CSC 标志物呈正相关。ALKBH5 在结直肠 CSCs 和患者来源的类器官（PDOs）中可诱导自我更新及干性标志物的表达。结肠干细胞特异性敲入 Alkbh5 会加速致癌物诱导的 CRC 发生，而在结肠干细胞特异性 Alkbh5 敲除小鼠中，肿瘤发生显著减弱。整合 RNA-seq、MeRIP-seq 与 Ribo-seq 数据分析发现 FAM84A 是 ALKBH5 的靶基因。ALKBH5 通过去甲基化 FAM84A mRNA 上的 m6A 修饰，导致该 mRNA 降解及表达下调。从机制上看，我们发现 FAM84A 通过与 β-连环蛋白（β-catenin）相互作用，促进其泛素化降解，从而抑制 CSCs。由于促进 CSCs 的扩增，ALKBH5 过表达在 CSCs、PDOs 以及转基因小鼠中引发化疗耐药。通过敲除 ALKBH5 或应用含有 siALKBH5 的病毒样纳米颗粒（VNPs-siALKBH5）进行干预，可与化疗协同作用，诱导源自 CSCs/PDOs 的异种移植瘤及 ALKBH5 敲除小鼠的肿瘤退缩。综上所述，本研究揭示 ALKBH5 对结直肠癌 CSCs 的维持至关重要，并为克服 CRC 化疗耐药提供了潜在治疗靶点。

### 第二部分 AI 大师评价

本研究系统阐明了 m6A 去甲基化酶 ALKBH5 在结直肠癌干细胞维持及化疗耐药形成中的关键作用。作者通过小鼠模型与多组学数据整合，发现 ALKBH5 可通过调控 FAM84A 的 mRNA 稳定性影响 β-catenin 信号通路，从而增强肿瘤干性与耐药性。研究还验证了靶向 ALKBH5 的干预能增强化疗效果、促进肿瘤退缩。该发现为结直肠癌干细胞干预及耐药克服提供了新的治疗思路，虽机制尚需进一步临床验证，但具显著的转化潜力。

---

## 2. 肿瘤来源载脂蛋白E赋予胰腺神经内分泌肿瘤对替莫唑胺的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390817)
**期刊：** Cell death & disease
**PMID：** 41390817
**DOI：** 10.1038/s41419-025-08317-1

### 第一部分 原文与翻译

**英文原标题：** Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors.

> **英文摘要：**
> Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated. Here, we demonstrate that the reprogramming of lipid metabolism regulates TMZ resistance in patients with pNETs. Via integrated multiomics sequencing, apolipoprotein E (APOE), which is a critical lipid carrier, was identified to be highly increased in the tissue and blood plasma of patients in the TMZ treatment group compared with those in the control group. Further mechanistic studies revealed that TMZ treatment promotes the expression and secretion of APOE, which binds to its surface receptor known as scavenger receptor class B member 1 (SCARB1), thus leading to increased uptake of exogenous lipids to remodel cellular lipid metabolism and activation of the homologous recombination repair (HRR) pathway to repair DNA damage via the β-catenin-BRCA1/2 axis. The interruption of APOE-mediated lipid uptake via a SCARB1 inhibitor named as block lipid transport-1 (BLT-1), suppressed TMZ-induced HRR activation and sensitized tumor cells to TMZ treatment in preclinical models, including PDCs, PDOs, and PDXs. In addition, APOE expression levels were shown to be positively correlated with BRCA1/2 expression in clinical specimens and online databases. This study reveals a new functional role of APOE that leads to chemoresistance in patient treatment. Our findings suggest the potential of combined administration of BLT-1 to overcome TMZ chemoresistance and improve treatments for patients with pNETs.

> **中文摘要：**
> 替莫唑胺（TMZ）是针对胰腺神经内分泌肿瘤（pNETs）患者的一线临床用药。然而，由于pNET细胞存在化疗耐药性，其治疗效果受到限制，而这一机制尚未得到充分阐明。本研究证明，脂质代谢的重编程可调控pNET患者对TMZ的耐药性。通过整合多组学测序分析发现，关键脂质载体载脂蛋白E（APOE）在TMZ治疗组患者的组织和血浆中显著升高，相较于对照组更为明显。进一步的机制研究表明，TMZ治疗可促进APOE的表达与分泌，后者与其表面受体——清道夫受体B类1成员（SCARB1）结合，从而增强外源脂质的摄取，重塑细胞脂质代谢，并通过β-链蛋白–BRCA1/2轴激活同源重组修复（HRR）通路以修复DNA损伤。通过SCARB1抑制剂阻断脂质转运物质1（BLT-1）抑制APOE介导的脂质摄取，可阻断TMZ诱导的HRR激活，并在包括PDCs、PDOs及PDXs在内的临床前模型中增强肿瘤细胞对TMZ的敏感性。此外，APOE的表达水平在临床样本及在线数据库中与BRCA1/2的表达呈正相关。本研究揭示了APOE在患者治疗中导致化疗耐药的新功能作用。研究结果提示，联合使用BLT-1可能克服TMZ耐药性并改善pNET患者的治疗效果。

### 第二部分 AI 大师评价

该研究聚焦于胰腺神经内分泌肿瘤对替莫唑胺的耐药机制，发现肿瘤来源的载脂蛋白E通过重塑脂质代谢并激活同源重组修复通路促进耐药性。研究采用多组学整合分析与体内外验证模型，揭示了APOE–SCARB1–β-catenin–BRCA1/2轴在化疗耐药中的关键作用。重要创新在于将脂质代谢与DNA修复通路联系起来，并提出通过SCARB1抑制剂BLT-1联合治疗可逆转耐药的策略。尽管结果具有潜在转化价值，但其临床依从性与长期安全性仍需进一步验证。

---

## 3. 非催化性DNA聚合酶ε亚基是一种NPF基序识别蛋白。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390769)
**期刊：** Nature communications
**PMID：** 41390769
**DOI：** 10.1038/s41467-025-67284-5

### 第一部分 原文与翻译

**英文原标题：** The non-catalytic DNA polymerase ε subunit is an NPF motif recognition protein.

> **英文摘要：**
> Short linear motifs (SLiMs) in disordered protein regions direct numerous protein-protein interactions, yet most remain uncharacterized. The Asn-Pro-Phe (NPF) motif is a well-known EH-domain ligand implicated in endocytosis, but here we reveal that the non-catalytic subunit of human DNA polymerase ε (POLE2) also serves as a general NPF-motif receptor. Using a quantitative "native holdup" assay, we find that POLE2 selectively binds diverse NPF-containing peptides, including canonical EH-domain ligands (e.g., SYNJ1) and previously uncharacterized motifs. Biochemical measurements and mutational analyses show that NPF motifs interact with a shallow pocket near the POLE2 C-terminus, and AlphaFold predictions confirm key roles for Y513, E520, and S522 in motif coordination. Proteome-scale affinity screens identify NPF-containing nuclear proteins (e.g., WDHD1, DONSON, TTF2) that bind POLE2 with micromolar affinities, and their motif mutations abolish binding in cell extracts. Although POLE2 primarily tethers the catalytic POLE subunit to replication forks, these results indicate that it can also recruit various NPF-bearing partners involved in replication, DNA repair, and transcription regulation. Notably, NPF motifs optimized for EH-domain binding can still associate with POLE2, highlighting the inherent degeneracy of SLiM-mediated networks. Overall, these findings establish POLE2 as a central hub possibly linking replication with other processes via broad NPF-motif recognition.

> **中文摘要：**
> 位于无序蛋白区域中的短线性基序（SLiM）调控着大量的蛋白质间相互作用，但其中大多数仍未被表征。Asn-Pro-Phe（NPF）基序是一种众所周知的EH结构域配体，与内吞作用有关，但本研究揭示，人类DNA聚合酶ε的非催化亚基（POLE2）也可作为一种普遍的NPF基序受体。通过定量的“native holdup”测定，我们发现POLE2能够选择性地结合多种含NPF序列的肽段，包括典型的EH结构域配体（如SYNJ1）以及先前未被表征的基序。生化测定与突变分析表明，NPF基序与POLE2 C末端附近的浅口袋相互作用，而AlphaFold预测进一步验证了Y513、E520和S522在基序配位中的关键作用。基于蛋白质组尺度的亲和筛选鉴定出若干含NPF基序的核蛋白（如WDHD1、DONSON、TTF2）可与POLE2以微摩尔级亲和力结合，并且其基序突变会在细胞提取物中消除结合。尽管POLE2的主要功能是将催化性POLE亚基锚定于复制叉，但研究结果显示它还可招募多种含NPF基序的伙伴蛋白，这些蛋白涉及DNA复制、修复及转录调控。值得注意的是，为EH结构域结合优化的NPF基序仍能与POLE2相互作用，揭示了SLiM介导网络的固有冗余性。总体而言，这些发现确立了POLE2作为一个潜在的中心枢纽，能够通过广泛的NPF基序识别将复制过程与其他细胞过程相联系。

### 第二部分 AI 大师评价

本研究系统揭示了DNA聚合酶ε的非催化亚基POLE2作为广谱NPF基序识别蛋白的新功能。作者结合定量结合实验、生化与突变分析以及AlphaFold结构预测，阐明了关键残基与结合口袋的分子基础。结果显示POLE2不仅参与复制复合物的稳固，还可能连接复制、修复及转录调控等过程，拓展了其生物学角色的理解。研究的创新性在于发现POLE2新的配体识别谱，但仍需进一步解析其在细胞生理与信号调控中的动态作用。

---

## 4. 压缩诱导的 NF-κB 激活通过醛类解毒维持受限环境中肿瘤细胞存活并促进转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390768)
**期刊：** Nature communications
**PMID：** 41390768
**DOI：** 10.1038/s41467-025-67452-7

### 第一部分 原文与翻译

**英文原标题：** Compression-induced NF-κB activation sustains tumor cell survival in confinement by detoxifying aldehydes and promotes metastasis.

> **英文摘要：**
> Metastasis remains the primary cause of cancer-related mortality. During dissemination, cancer cells must navigate spatially confined microenvironments, yet the underlying metabolic adaptations that facilitate this process remain unclear. Here, through an in vivo CRISPR screen targeting metabolic enzymes, we identify aldehyde dehydrogenase 1 family member B1 (ALDH1B1) as essential for tumor cell survival in confining capillaries. Mechanistically, compressive force induces casein kinase 2 alpha 3 (CSK23) to phosphorylate kappa-B kinase subunit beta (IKKβ) at Ser177/181, which activates the nuclear factor kappa B (NF-κB) pathway and upregulates ALDH1B1. The upregulation of ALDH1B1 enhances aldehyde detoxification, which suppresses ferroptosis and promotes tumor cell survival during migration through the capillaries, thereby facilitating metastasis. Importantly, genetic or pharmacological inhibition of CSK23 or ALDH1B1 effectively impairs metastasis. In lung cancer patients, confined tumor cells exhibit higher levels of ALDH1B1 and NF-κB activation, which correlates with metastatic recurrence. Our findings reveal a mechano-metabolic pathway that promotes metastasis and suggest CSK23 and ALDH1B1 as potential therapeutic targets.

> **中文摘要：**
> 转移仍然是癌症相关死亡的主要原因。在扩散过程中，癌细胞必须在空间受限的微环境中迁移，但促进这一过程的代谢适应机制尚不清楚。本研究通过针对代谢酶的体内 CRISPR 筛选，鉴定到醛脱氢酶1家族成员 B1（ALDH1B1）对于肿瘤细胞在受限毛细血管中的存活是必需的。在机制上，压缩力诱导酪蛋白激酶2 α3（CSK23）在 Ser177/181 位点磷酸化 κB 激酶 β 亚基（IKKβ），从而激活核因子 κB（NF-κB）通路并上调 ALDH1B1 的表达。ALDH1B1 的上调增强了醛类物质的解毒作用，从而抑制铁死亡并在毛细血管迁移过程中促进肿瘤细胞存活，最终促进转移。重要的是，对 CSK23 或 ALDH1B1 的基因学或药理学抑制可有效削弱转移。在肺癌患者中，受限状态下的肿瘤细胞表现出更高水平的 ALDH1B1 和 NF-κB 激活，并与转移复发相关。我们的研究揭示了一条促进转移的机械-代谢通路，并提示 CSK23 和 ALDH1B1 可作为潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究围绕肿瘤细胞在迁移中应对机械压缩的适应机制展开，结合体内 CRISPR 代谢酶筛选与信号通路分析，揭示了压缩应力通过 CSK23 激活 NF-κB 通路上调 ALDH1B1，从而增强醛类解毒、抑制铁死亡并促进转移。该研究创新性地提出了“机械压缩–代谢适应–转移促进”的新机制，兼顾分子生物学与临床相关性。其潜在局限在于模型主要基于特定肿瘤类型，是否普遍适用于其他肿瘤仍需进一步验证。

---

## 5. 用于生物电子学的无触发形状记忆水凝胶 4D 打印：迈向自适应基底的设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390766)
**期刊：** Nature communications
**PMID：** 41390766
**DOI：** 10.1038/s41467-025-67323-1

### 第一部分 原文与翻译

**英文原标题：** 4D printing of trigger-free shape-memory hydrogels towards self-adaptive substrates for bioelectronics.

> **英文摘要：**
> Shape-changing smart substrates are revolutionizing implantable bioelectronics by offering minimal invasiveness and self-adaptive geometric conformity. However, precise manipulation of shapeshifting, which is critical for the successful implantation, are hindered by triggering accessibility and cumbersome customization. Here we introduce a digital 4D printing technique for fabricating customized shape memory hydrogel substrates enabling trigger-free shapeshifting with predefined onset periods. By controlling spatio-temporal light exposure, pixelated polymer sheets with heterogeneous networks are obtained, yielding intricate 3D original shapes after monomer removal. Meanwhile, spatially controlled onset time of the programmable shape recovery is introduced, attributed to local variation of polymeric network structure and the corresponding thermally-induced phase separation. This approach allows the complex 3D objects to execute autonomous multi-stage shape recovery through a single-step digital exposure process, which is not offered by existing techniques. In addition, the material exhibits negligible inflammation proven by in-vivo testing of male mice experiments. Demonstrated with self-winding bioelectronics, this method advances time-dependent adaptability of implantable devices and expands the functional scope of bioelectronics.

> **中文摘要：**
> 可变形的智能基底正通过实现微创性与自适应几何贴合，正在革新植入式生物电子学。然而，对于形状变化的精确调控——这是确保成功植入的关键——仍受到触发方式受限及繁琐定制流程的阻碍。本研究提出了一种数字化 4D 打印技术，用于制备可定制的形状记忆水凝胶基底，实现具有预设启动时间的无触发形变。通过控制时空光照分布，可获得具有异质网络的像素化聚合物薄片，在去除单体后形成复杂的三维原始形态。同时，引入了可编程形状恢复的空间可控启动时间，这归因于聚合物网络结构的局部差异及相应的热诱导相分离。该方法使复杂三维结构能通过单步数字曝光过程实现自主的多阶段形状恢复，这是现有技术所不具备的。此外，体内雄性小鼠实验显示该材料几乎不引发炎症反应。通过自卷曲生物电子器件验证，本方法提升了植入设备的时间依赖自适应性，并拓宽了生物电子学的功能边界。

### 第二部分 AI 大师评价

该研究旨在发展一种无需外部触发的形状记忆水凝胶 4D 打印策略，以实现可编程、自适应的生物电子器件基底。作者通过数字化光照控制在单步曝光中实现网络结构的空间异质性，从而赋予材料时间序列的多阶段形变能力。体内实验验证了其优异的生物相容性和低炎症反应。该技术在可植入器件的微创化与自适应性方面展现出明显创新，但后续仍需探讨其在复杂生理环境中的长期稳定性与规模化制造潜力。

---

## 6. HIV诱导的感染性CD4+ T细胞唾液酸糖链促进其逃避免疫细胞介导的杀伤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390763)
**期刊：** Nature communications
**PMID：** 41390763
**DOI：** 10.1038/s41467-025-66540-y

### 第一部分 原文与翻译

**英文原标题：** HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing.

> **英文摘要：**
> Sialic acid-containing glycans (sialoglycans) on pathological cells interact with Siglecs, glyco-immune checkpoint receptors expressed on myeloid cells, suppressing the cytotoxic functions of these immune cells. Using targeted glycomic analyses and gene editing, we show that HIV infection reprograms the glycosylation machinery of infected cells to increase the expression of the sialoglycan ligands for Siglec-3, -7, and -9. These ligands engage Siglecs on myeloid cells, impairing their ability to target HIV-infected cells. Selective disruption of these interactions using 10-1074-SiaD, an HIV-specific antibody conjugated to sialidase, an enzyme that removes sialic acids, significantly enhances monocyte- and neutrophil-mediated killing of HIV-infected cells in autologous assays. Treatment with 10-1074-SiaD in female humanized mice infected with HIV reduces viral load and decreases inflammation. These findings reveal an immune evasion mechanism exploited by HIV to evade myeloid cell immune surveillance and highlight the potential of targeting sialoglycan-Siglec interactions to improve immune clearance of HIV-infected cells.

> **中文摘要：**
> 病理细胞表面的含有唾液酸的糖链（唾液酸糖链）可与髓系细胞上表达的糖型免疫检查点受体Siglec相互作用，从而抑制这些免疫细胞的细胞毒性功能。通过靶向糖组学分析和基因编辑，本研究表明，HIV感染会重编程受感染细胞的糖基化机制，增强针对Siglec-3、Siglec-7和Siglec-9的唾液酸糖链配体的表达。这些配体与髓系细胞上的Siglec结合，削弱了后者识别并清除HIV感染细胞的能力。利用10-1074-SiaD（一种与去唾液酸酶相结合的特异性抗HIV抗体）选择性破坏这些相互作用，能显著增强单核细胞和中性粒细胞在自体检测中对HIV感染细胞的杀伤效应。在HIV感染的女性人源化小鼠中应用10-1074-SiaD治疗可降低病毒载量并减轻炎症。这些研究结果揭示了HIV利用唾液酸糖链介导的免疫逃逸机制，以规避髓系细胞的免疫监视，并强调了以靶向唾液酸糖链-Siglec相互作用来增强HIV感染细胞免疫清除的潜在价值。

### 第二部分 AI 大师评价

本研究揭示了HIV通过诱导受感染CD4+ T细胞表面唾液酸糖链表达，从而抑制髓系细胞介导的清除作用的免疫逃逸机制。作者结合糖组学分析与基因编辑实验，明确了Siglec受体在这一过程中发挥的关键作用。通过设计去唾液酸酶融合抗体10-1074-SiaD，有效恢复了髓系细胞的抗病毒效能，并在动物模型中降低了病毒载量。该研究为针对HIV免疫清除的新型免疫治疗策略提供了创新思路，但未来仍需评估其在不同宿主免疫环境中的安全性与长期疗效。

---

## 7. 靶向伴侣介导的自噬可抑制胶质母细胞瘤干细胞特性并恢复抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390755)
**期刊：** Nature communications
**PMID：** 41390755
**DOI：** 10.1038/s41467-025-67119-3

### 第一部分 原文与翻译

**英文原标题：** Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity.

> **英文摘要：**
> Chaperone-mediated autophagy (CMA) is a selective autophagic process essential for maintaining cellular quality and responding to stress. Dysregulation of the CMA pathway is increasingly recognized in various cancers, yet the mechanisms behind CMA hyperactivation in cancer cells remain unclear. Here, we show that CMA is upregulated in patient-derived glioblastoma stem cells (GSCs), indicated by a significant increase in the lysosomal abundance of the CMA receptor, lysosome-associated membrane protein 2 A (LAMP2A). This increase results from MST4-mediated phosphorylation of LAMP2A, enhancing its stability and promoting homotrimer formation while inhibiting degradation by Cathepsin A. CMA supports GSC proliferation and self-renewal by activating mTORC1 through the selective degradation of its negative regulators, TSC1 and TSC2. Additionally, CMA is involved in epigenetic silencing of the cGAS-STING pathway, promoting tumor immune escape via lysosomal degradation of the DNA demethylase TET3. Inhibition of CMA synergizes with immune checkpoint therapy in glioblastoma models, highlighting a potential therapeutic target.

> **中文摘要：**
> 伴侣介导的自噬（CMA）是一种选择性自噬过程，对于维持细胞质量和应对应激至关重要。CMA通路的失调在多种癌症中受到越来越多的关注，然而癌细胞中CMA过度活化的机制仍不清楚。在本研究中，我们发现CMA在来源于患者的胶质母细胞瘤干细胞（GSCs）中上调，这表现为CMA受体——溶酶体相关膜蛋白2A（LAMP2A）在溶酶体中的含量显著增加。这种增加是由MST4介导的LAMP2A磷酸化所致，增强了其稳定性，促进同源三聚体形成，同时抑制了组织蛋白酶A的降解。CMA通过选择性降解mTORC1的负调控因子TSC1和TSC2，从而激活mTORC1，支持GSC的增殖和自我更新。此外，CMA参与了cGAS-STING通路的表观遗传沉默，通过溶酶体降解DNA去甲基化酶TET3来促进肿瘤免疫逃逸。抑制CMA在胶质母细胞瘤模型中与免疫检查点治疗具有协同作用，揭示了一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究聚焦于伴侣介导的自噬在胶质母细胞瘤干细胞中的作用机制，系统揭示了LAMP2A磷酸化介导CMA上调及其对肿瘤干性和免疫逃逸的双重影响。研究发现CMA通过mTORC1激活及TET3降解促进肿瘤生长与免疫抑制，并证实抑制CMA可增强免疫检查点治疗效果。该工作在机制层面链接了自噬调控与肿瘤免疫，具有较高创新价值。局限性在于目前主要基于实验模型，临床可转化性尚待进一步验证。

---

## 8. 嵌合减毒活寨卡疫苗在非人灵长类中与保护相关的免疫学及转录组学特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390746)
**期刊：** Nature communications
**PMID：** 41390746
**DOI：** 10.1038/s41467-025-66073-4

### 第一部分 原文与翻译

**英文原标题：** Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates.

> **英文摘要：**
> Zika virus (ZIKV) is typically mild in humans but can cause severe congenital defects when contracted during pregnancy. Chimeric live-attenuated vaccine candidate YF-ZIK previously showed protective efficacy against lethal infection and developmental abnormalities in mice after a single dose. Here we demonstrate that YF-ZIK is safe, induces antiviral immunity, and protects rhesus macaques against high-dose experimental challenge. A single subcutaneous dose elicits neutralizing antibodies within 7-14 days, boosted by a second dose at 4 weeks. Passive serum transfer protects AG129 mice, supporting antibodies as a correlate of protection. YF-ZIK triggers balanced Th1/Th2 responses and a transcriptional profile resembling the licensed YF17D vaccine, involving multiple pathways favoring polyvalent immunity. Upon challenge, vaccinated macaques show no detectable viral RNA nor seroconversion to anti-ZIKV NS1 antibodies, suggesting sterilizing immunity. Systems analysis identifies TNFRSF17 as predictor of antibody responses to YF-ZIK, and GNAS and CD207 (Langerin) as potentially linked to clinical outcomes. The favorable preclinical safety, immunogenicity, and efficacy of YF-ZIK justify its future evaluation in humans.

> **中文摘要：**
> 寨卡病毒（ZIKV）在人类中通常引起轻微感染，但孕期感染可导致严重的先天性缺陷。先前的研究表明，嵌合减毒活疫苗候选物 YF-ZIK 在小鼠中单次接种即可对致死性感染和发育异常产生保护效果。在本研究中，我们证明 YF-ZIK 是安全的，能够诱导抗病毒免疫，并可保护恒河猴免受高剂量实验性挑战。单次皮下注射后 7–14 天内可产生中和抗体，4 周后追加一剂可进一步增强免疫应答。被动血清转移对 AG129 小鼠具有保护作用，支持抗体是保护性的重要相关指标。YF-ZIK 能够诱导平衡的 Th1/Th2 免疫反应，并呈现出类似已获许可的黄热 17D 疫苗的转录特征，涉及多条促进多价免疫的信号通路。在病毒挑战后，接种的恒河猴未检测到病毒 RNA，也未出现针对 ZIKV NS1 抗体的血清转化，提示其可能产生灭菌性免疫。系统分析确定 TNFRSF17 是预测 YF-ZIK 抗体应答的指标基因，而 GNAS 和 CD207（Langerin）可能与临床结局相关。YF-ZIK 优异的临床前安全性、免疫原性和保护效果支持其在人体中的进一步评估。

### 第二部分 AI 大师评价

该研究旨在通过免疫学与转录组学分析，揭示嵌合减毒活寨卡疫苗 YF-ZIK 在非人灵长类中的免疫特征与保护机制。作者采用多维度实验，包括中和抗体检测、细胞免疫分析以及基因表达谱比较，系统评估了其安全性与免疫效果。结果显示 YF-ZIK 能诱导强而平衡的免疫反应，并实现灭菌性保护，同时识别出与抗体应答相关的关键分子。该研究为寨卡疫苗的临床转化提供了有力证据，其创新性在于结合系统生物学揭示疫苗免疫相关分子网络，但仍需在人群中进一步验证其长期安全性与效力。

---

## 9. 基于蛋白质-核酸语言模型辅助的精确且紧凑的腺嘌呤碱基编辑器设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390734)
**期刊：** Nature communications
**PMID：** 41390734
**DOI：** 10.1038/s41467-025-65311-z

### 第一部分 原文与翻译

**英文原标题：** Protein-nucleic acid language model-assisted design of precise and compact adenine base editor.

> **英文摘要：**
> Adenine base editors (ABEs) are powerful tools for gene therapy. However, efficient version of ABEs (e.g. ABE8e) always induce excessive bystander and off-target editing events and are large in size, hindering their potential in clinical disease treatment. Here, we develop a pre-trained Protein-Nucleic Acid Constrained Language Model to design ABE8e with high activity, reduced editing window and decreased size. By further engineering, the smallest ABE8e- PNLM-pcABE- with a 27% size reduction, exhibits high activity, precise 3-nt editing window, and reduced off-target events near background level in HEK293T cells. Compared to ABE8e, PNLM-pcABE has up to 133.5-fold precision improvement in pathogenic mutation correction. By PNLM-pcABE, the albino mouse model carrying desired base mutation is nearly 100% obtained via zygotes microinjection and the expression of PCSK9 substantially decreases in mice receiving in vivo delivery with lipid nanoparticle (LNP), indicating their great potential in gene therapy and disease modeling.

> **中文摘要：**
> 腺嘌呤碱基编辑器（ABE）是基因治疗的有力工具。然而，高效版本的ABE（如 ABE8e）往往会产生过多的伴随和脱靶编辑事件，同时体积较大，从而限制了其在临床疾病治疗中的潜力。本研究开发了一种预训练的蛋白质-核酸约束语言模型，用以设计具有高活性、缩小编辑窗口并实现尺寸减小的 ABE8e。经过进一步的工程化优化，获得了最小化的 ABE8e 变体 PNLM-pcABE，其尺寸减少了27%，在 HEK293T 细胞中表现出高活性、精确的3个核苷酸编辑窗口，以及脱靶事件接近背景水平的特征。与 ABE8e 相比，PNLM-pcABE 在致病突变校正的精确度方面提升了高达133.5倍。利用 PNLM-pcABE，通过合子显微注射几乎可以100%获得携带目标碱基突变的白化小鼠模型，并且通过脂质纳米颗粒（LNP）体内递送后，小鼠体内 PCSK9 的表达显著降低，表明该系统在基因治疗及疾病模型构建中具有巨大潜力。

### 第二部分 AI 大师评价

本文提出了一种基于蛋白质-核酸约束语言模型（PNLM）的腺嘌呤碱基编辑器优化策略，实现了ABE8e的精准与小型化设计。研究团队成功研制出具备更高活性、更窄编辑窗口和显著减脱靶效应的PNLM-pcABE，并验证了其在细胞和动物模型中的高效性能。这一模型驱动的编辑器设计为人工智能与基因编辑技术的融合提供了新范式。其创新性在于多尺度信息整合与精度优化，但临床应用的安全性及跨物种普适性仍需进一步验证。

---

## 10. 靶向LRBA诱导CTLA4降解并激发抗肿瘤免疫以用于癌症免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390689)
**期刊：** Nature communications
**PMID：** 41390689
**DOI：** 10.1038/s41467-025-67365-5

### 第一部分 原文与翻译

**英文原标题：** Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy.

> **英文摘要：**
> The lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency causes severe autoimmune diseases and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) loss in humans. However, the impact of LRBA on antitumor immunity remains understudied. Here we show the important role of LRBA in antitumor immunity and develop small molecules targeting LRBA for cancer immunotherapy. Interestingly, LRBA is negatively associated with antitumor immunity in human patients and mouse models. Using high-throughput screening and subsequent hit optimization, we discover a small molecule LC427 that facilitates the lysosomal degradation of CTLA4 and bolsters survival of activated T cells by binding directly to LRBA and inhibiting the LRBA-CTLA4 interaction. Orally administrated LC427 increases tumor-infiltrating CD8 T cells and displays effective antitumor activity in multiple mouse tumor models. Notably, LC427 does not induce immune-related adverse events observed with immune checkpoint inhibitors in colitis models. Our study demonstrates that targeting LRBA offers an effective strategy for cancer immunotherapy.

> **中文摘要：**
> 脂多糖响应性米色样锚定蛋白（LRBA）的缺乏会导致人类发生严重的自身免疫性疾病，并引起细胞毒性T淋巴细胞相关蛋白4（CTLA4）的丢失。然而，LRBA对抗肿瘤免疫的影响尚未得到充分研究。在本研究中，我们揭示了LRBA在抗肿瘤免疫中的重要作用，并开发了靶向LRBA的小分子用于癌症免疫治疗。有趣的是，LRBA在患者样本和小鼠模型中均与抗肿瘤免疫呈负相关。通过高通量筛选及后续命中化合物优化，我们发现了一种小分子LC427，它能直接结合LRBA并抑制LRBA与CTLA4的相互作用，从而促进CTLA4的溶酶体降解并增强活化T细胞的存活。口服给药的LC427可增加肿瘤浸润CD8 T细胞的数量，并在多种小鼠肿瘤模型中显示出显著的抗肿瘤活性。值得注意的是，在小鼠结肠炎模型中，LC427并未引起类似免疫检查点抑制剂所观察到的免疫相关不良事件。本研究表明，靶向LRBA为癌症免疫治疗提供了一种有效的新策略。

### 第二部分 AI 大师评价

该研究围绕LRBA在抗肿瘤免疫中的作用展开，揭示其与CTLA4稳定性及免疫调控的关键关系。作者利用高通量筛选发现小分子LC427，可通过促进CTLA4溶酶体降解增强T细胞功能，从而实现抗肿瘤效果。动物实验显示LC427在多种肿瘤模型中具有良好疗效且无明显免疫毒性，体现其潜在临床应用价值。研究创新性在于发现LRBA作为免疫调控靶点的可行性，但后续仍需评估其在人类系统中的长期安全性与作用机制。

---

## 11. 全身照射后小鼠模型中骨微环境破坏与免疫恢复的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390678)
**期刊：** Cell death & disease
**PMID：** 41390678
**DOI：** 10.1038/s41419-025-08303-7

### 第一部分 原文与翻译

**英文原标题：** Disrupted bone microenvironment and immune recovery following total body irradiation in a murine model.

> **英文摘要：**
> Irradiation is an effective therapy for eliminating cancer cells and serves as a critical preparative regimen for hematopoietic stem cell transplantation (HSCT). However, irradiation affects healthy tissue, disrupting bone tissue and bone marrow homeostasis, which leads to skeletal and immune dysfunction. To investigate these effects, we used a female murine model to explore the mechanisms underlying the skeletal damage caused by total body irradiation. Experiments were carried out over a 12-week period of total body irradiation and HSCT, supplemented by an acute study involving only total body irradiation and osteoclastogenesis. Irradiation resulted in a depletion of bone marrow immune cells, followed by an increase in bone marrow cellularity 12 weeks after irradiation and HSCT compared to naive controls, indicating late-stage local immune induction. Cortical and trabecular bone loss appeared 2 weeks post-irradiation and HSCT and persisted throughout the study. This bone damage was accompanied by a sustained increase in apoptotic cells in the bone marrow within 6 h post-irradiation and persisted for up to 12 weeks after irradiation and HSCT. This was coupled with elevated local expression of the pro-apoptotic Bax gene and an increase in TGF-β1, a gene associated with the clearance of apoptotic cells. In vitro studies demonstrated that macrophages and pre-osteoclasts, but not fully differentiated osteoclasts, efficiently cleared apoptotic cells, resulting in increased levels of TGF-β1 in the culture supernatant. While the clearance of apoptotic cells and associated TGF-β1 signaling were evident, their direct role in skeletal outcomes remains unclear. These findings suggest that persistent apoptotic cells contribute to impaired bone remodeling, potentially affecting osteoclast function and the bone microenvironment. Additional research is needed to investigate whether targeting apoptotic cell clearance can mitigate bone damage and promote skeletal recovery following irradiation.

> **中文摘要：**
> 放射治疗是消灭癌细胞的有效手段，同时也是造血干细胞移植（HSCT）的关键预处理方案。然而，放疗也会影响健康组织，破坏骨组织和骨髓的稳态，导致骨骼及免疫系统功能障碍。为探究这些影响，我们采用雌性小鼠模型，研究全身照射引起骨损伤的机制。实验在为期12周的全身照射和HSCT过程中进行，并辅以仅涉及全身照射与破骨细胞生成的急性实验。照射导致骨髓免疫细胞耗竭，随后在照射和HSCT后12周，骨髓细胞性较对照组升高，提示存在晚期局部免疫激活。皮质骨和松质骨的丢失在照射和HSCT后2周即出现，并贯穿整个研究过程。此类骨损伤伴随骨髓中凋亡细胞自照射后6小时内持续升高的现象，并在照射和HSCT后持续长达12周。这一过程伴随着促凋亡基因Bax的局部表达升高，以及与凋亡细胞清除相关的TGF-β1基因增加。体外研究显示，巨噬细胞和前体破骨细胞能够有效清除凋亡细胞，而完全分化的破骨细胞则无此能力，此过程导致培养上清液中TGF-β1水平升高。虽然凋亡细胞清除及其相关的TGF-β1信号已获证实，但其对骨损伤结果的直接作用尚不明确。该研究结果提示，持续存在的凋亡细胞可能导致骨重塑受损，影响破骨细胞功能和骨微环境。进一步研究应探讨靶向凋亡细胞清除是否有助于减轻放疗引起的骨损伤并促进骨骼恢复。

### 第二部分 AI 大师评价

本研究旨在揭示全身照射后骨组织和免疫系统的损伤机制，利用小鼠模型结合长期和急性实验的设计，系统评估骨微环境和免疫恢复过程。研究发现放疗后骨髓细胞凋亡持续存在，并伴随骨量丢失、Bax及TGF-β1上调，提示凋亡细胞清除受损可能干扰骨重塑。作者通过体外实验识别了负责清除凋亡细胞的关键细胞类型，为理解放射引起的骨微环境失衡提供新视角。该研究创新性在于将凋亡清除与骨损伤关联，但尚需进一步机制验证及临床转化研究。

---

## 12. miR-101/METTL3 轴通过干扰 FOXG1/EIF3J-AS1 结合在胶质瘤中诱导自噬。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390674)
**期刊：** Cell death & disease
**PMID：** 41390674
**DOI：** 10.1038/s41419-025-08285-6

### 第一部分 原文与翻译

**英文原标题：** miR-101/METTL3 axis induces autophagy by interrupting FOXG1/EIF3J-AS1 binding in gliomas.

> **英文摘要：**
> The role of autophagy in glioma remains controversial, with long non-coding RNAs (lncRNAs) playing a crucial role in its regulation. N6-methyladenosine (m6A) modification influences lncRNA expression and function. Specifically, lncRNA EIF3J-AS1 acts as an oncogene in glioma, yet the mechanisms driving its upregulation remain unclear. This study demonstrates that EIF3J-AS1 expression is significantly elevated in glioblastoma multiforme (GBM) compared to low-grade glioma (LGG) and normal brain tissue. RNA sequencing (RNA-seq) identified EIF3J-AS1 as a target of the tumor suppressor miR-101, with functional assays showing its role in promoting glioma cell proliferation, inhibiting autophagy, and enhancing tumorigenesis in vivo. Methylated RNA immunoprecipitation (MeRIP) and bioinformatics analyses confirmed m6A modification of EIF3J-AS1, which correlates positively with the m6A methyltransferase METTL3 in glioma tissues. Mechanistically, METTL3 promotes m6A-dependent binding of EIF3J-AS1 to the transcription factor FOXG1. RNA-seq screening further identified macrophage migration inhibitory factor (MIF), an autophagy-promoting gene, as a downstream target of both METTL3 and EIF3J-AS1. Functional validation revealed that the METTL3/EIF3J-AS1/FOXG1 axis suppresses autophagy via MIF downregulation. Conversely, miR-101-mediated suppression of METTL3 disrupts EIF3J-AS1-FOXG1 binding, restoring MIF expression and promoting autophagy. These findings highlight EIF3J-AS1 and METTL3 as potential therapeutic targets, with disruption of EIF3J-AS1-FOXG1 interactions representing a novel autophagy-modulating strategy for glioma treatment.

> **中文摘要：**
> 自噬在胶质瘤中的作用仍存在争议，而长链非编码 RNA（lncRNA）在其调控中起关键作用。N6-甲基腺苷（m6A）修饰会影响 lncRNA 的表达和功能。具体而言，lncRNA EIF3J-AS1 在胶质瘤中表现为癌基因，但其上调机制尚不清楚。本研究表明，与低级别胶质瘤（LGG）和正常脑组织相比，EIF3J-AS1 在多形性胶质母细胞瘤（GBM）中显著升高。RNA 测序（RNA-seq）确定 EIF3J-AS1 是肿瘤抑制因子 miR-101 的靶基因，功能实验表明其促进胶质瘤细胞增殖、抑制自噬并增强体内致瘤性。甲基化 RNA 免疫共沉淀（MeRIP）和生物信息分析证实 EIF3J-AS1 存在 m6A 修饰，并在胶质瘤组织中与 m6A 甲基转移酶 METTL3 表达呈正相关。在机制上，METTL3 促进 EIF3J-AS1 与转录因子 FOXG1 的 m6A 依赖性结合。进一步的 RNA-seq 筛选鉴定出巨噬细胞迁移抑制因子（MIF），一个促进自噬的基因，作为 METTL3 和 EIF3J-AS1 的下游靶标。功能验证表明，METTL3/EIF3J-AS1/FOXG1 轴通过下调 MIF 表达抑制自噬。相反，miR-101 介导的 METTL3 抑制可破坏 EIF3J-AS1-FOXG1 结合，恢复 MIF 表达并促进自噬。这些发现强调了 EIF3J-AS1 和 METTL3 作为潜在治疗靶点的重要性，且破坏 EIF3J-AS1-FOXG1 相互作用可能代表调节胶质瘤自噬的新策略。

### 第二部分 AI 大师评价

该研究通过揭示 miR-101/METTL3/EIF3J-AS1/FOXG1/MIF 信号通路在胶质瘤自噬调控中的作用，阐明了 lncRNA EIF3J-AS1 上调的分子机制。研究结合 RNA-seq、MeRIP 及功能实验，系统揭示 m6A 修饰对自噬途径的影响。创新性在于提出干扰 EIF3J-AS1-FOXG1 结合可作为诱导自噬的潜在治疗策略。局限在于尚需在临床样本和体内模型中进一步验证其治疗可行性。该机制的解析为靶向自噬调控的胶质瘤疗法提供了新的思路。

---

## 13. 构建靶向 HLA-G 的细胞外囊泡纳米平台，通过精准药物递送提升癌症治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390497)
**期刊：** Nature communications
**PMID：** 41390497
**DOI：** 10.1038/s41467-025-66451-y

### 第一部分 原文与翻译

**英文原标题：** Engineering HLA-G-targeted extracellular vesicles nanoplatform for enhanced cancer therapy through precise cancer drug delivery.

> **英文摘要：**
> Extracellular vesicles (EVs) hold great potential as a therapeutic delivery system for cancer treatment. Here, we develop an innovative targeted drug delivery platform, human leukocyte antigen-G-VHH antibody-modified EV (α-HLA-G-EV), to enhance therapeutic efficacy. A genetically engineered HEK293T stable clone is utilized to produce α-HLA-G-EV, which are subsequently loaded with chemotherapeutic agents to create HLA-G-targeting drug-loaded EVs (drug@α-HLA-G-EV). The cytotoxicity of drug@α-HLA-G-EV is assessed in various cancer cell lines, demonstrating superior tumor targeting and therapeutic efficacy compared to standard chemotherapies. In vivo experiments using xenograft NPG mouse models, established with MDA-MB-231 and U87 cell lines, further confirm the enhanced antitumor activity of Doxorubicin@α-HLA-G-EV and Temozolomide@α-HLA-G-EV. These findings are consistent with results observed in patient-derived breast cancer and GBM cell models. Additionally, drug@α-HLA-G-EV causes far less damage to normal organs than Lipo-Dox. These findings highlight the potential of α-HLA-G-EV as a versatile platform for precise and efficient cancer treatment.

> **中文摘要：**
> 细胞外囊泡（EVs）作为癌症治疗中的治疗性递送系统，具有巨大潜力。在本研究中，我们开发了一种创新性的靶向药物递送平台——人白细胞抗原-G-VHH抗体修饰的EV（α-HLA-G-EV），以提高治疗效果。利用基因工程改造的HEK293T稳定克隆细胞生产α-HLA-G-EV，随后将其负载化疗药物，构建靶向HLA-G的药物负载型EV（drug@α-HLA-G-EV）。在多种癌细胞系中评估了drug@α-HLA-G-EV的细胞毒性，结果显示与常规化疗相比具有更优异的肿瘤靶向性和治疗效能。在以MDA-MB-231和U87细胞系建立的异种移植NPG小鼠模型中，体内实验进一步证实Doxorubicin@α-HLA-G-EV和Temozolomide@α-HLA-G-EV具备增强的抗肿瘤活性。这些结果与患者来源乳腺癌和胶质母细胞瘤（GBM）模型中的观察结果一致。此外，drug@α-HLA-G-EV对正常器官造成的损伤远低于Lipo-Dox。这些发现表明，α-HLA-G-EV具有作为精准高效癌症治疗多功能平台的潜力。

### 第二部分 AI 大师评价

该研究旨在构建一种以HLA-G为靶点的细胞外囊泡药物递送平台，以提高抗癌治疗的精准性与疗效。研究团队通过基因工程修饰HEK293T细胞，制备出带有人源VHH抗体的α-HLA-G-EV，并负载多种化疗药物。体内外实验均验证其卓越的肿瘤靶向性、增强的抗肿瘤效应及较低的系统毒性。此平台在基于免疫识别的精准药物递送上具有显著创新性，但其大规模生产及临床转化仍需进一步探索。

---

## 14. 通过降低 eIF5A 活性抑制翻译延伸可诱导起始的反馈性抑制，从而限制肿瘤细胞增殖

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390489)
**期刊：** Nature communications
**PMID：** 41390489
**DOI：** 10.1038/s41467-025-66531-z

### 第一部分 原文与翻译

**英文原标题：** Inhibiting translation elongation by reducing eIF5A activity induces feedback inhibition of initiation, limiting tumour cell proliferation.

> **英文摘要：**
> Cancer development is associated with dysregulation of the translatome, and targeting canonical eukaryotic initiation and elongation factors can offer treatment avenues for various neoplasms. Emerging evidence indicates that dysregulated mRNA elongation, involving alterations in eEF2 activity and eIF5A expression, also contributes to tumour cell growth. In this study, we investigate whether targeting eIF5A with the inhibitor GC7 is a viable strategy to curtail aberrant cell growth. Our findings demonstrate that inhibiting elongation by reducing eIF5A activity induces feedback inhibition of initiation through eIF2α phosphorylation, decreasing ternary complex formation and shutting down bulk protein synthesis. Employing dynamic SILAC, we identify proteins impacted by reduced eIF5A activity, and show their decreased translation results from feedback inhibition to initiation or other processes downstream of eIF5A. Decreased eIF5A activity impairs mitochondrial function, which activates signalling through HRI to eIF2α phosphorylation, reducing cancer cell proliferation. These effects are reversed by treatment with the integrated stress response inhibitor, implying that the impact of GC7 on cancer cell proliferation is mediated via translation initiation rather than elongation inhibition. These data suggest that eIF5A inhibition could be used to target cancer cells that depend on mitochondrial function for their proliferation and survival.

> **中文摘要：**
> 癌症的发生与转录组的失调相关，针对典型的真核起始与延伸因子可为多种肿瘤提供治疗途径。新兴证据显示，mRNA 延伸过程的异常调控，包括 eEF2 活性和 eIF5A 表达的改变，也会促进肿瘤细胞生长。在本研究中，我们探讨了利用抑制剂 GC7 靶向 eIF5A 是否是一种抑制异常细胞生长的可行策略。我们的研究结果表明，通过降低 eIF5A 活性来抑制翻译延伸，可通过 eIF2α 磷酸化诱导起始阶段的反馈性抑制，从而减少三元复合物形成并关闭整体蛋白质合成。利用动态 SILAC 技术，我们识别了因 eIF5A 活性降低而受影响的蛋白，并显示这些蛋白翻译减少的原因来自起始阶段的反馈抑制或 eIF5A 下游其他过程。eIF5A 活性下降会损伤线粒体功能，该损伤激活通过 HRI 到 eIF2α 磷酸化的信号通路，从而降低癌细胞增殖。这些效应可通过应用整合性应激反应抑制剂而逆转，说明 GC7 对癌细胞增殖的影响主要经由翻译起始而非延伸抑制介导。这些数据提示，eIF5A 抑制可能用于靶向那些依赖线粒体功能进行增殖和存活的癌细胞。

### 第二部分 AI 大师评价

该研究聚焦于翻译调控在肿瘤细胞生长中的作用，特别是 eIF5A 在延伸阶段的功能。研究者通过药物干预与动态 SILAC 技术揭示，降低 eIF5A 活性不仅抑制延伸，还通过 eIF2α 磷酸化反馈性抑制起始，从而广泛抑制蛋白合成。研究进一步发现，线粒体功能受损与应激信号通路的激活密切相关，且该效应可被整合性应激反应抑制剂逆转。整体而言，工作揭示了翻译起始与延伸之间的动态耦联机制，提出了 eIF5A 作为潜在靶点的新治疗策略，但仍需在体内模型和不同肿瘤类型中进一步验证。

---

## 15. 肠道微生物群可预测糖尿病前期对膳食纤维的个体化反应：一项随机、开放标签试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390484)
**期刊：** Nature communications
**PMID：** 41390484
**DOI：** 10.1038/s41467-025-66498-x

### 第一部分 原文与翻译

**英文原标题：** Gut microbiome predicts personalized responses to dietary fiber in prediabetes: a randomized, open-label trial.

> **英文摘要：**
> Gut microbiota contributes to prediabetes progression, however, whether microbiota features can guide targeted prevention and treatment for diabetes requires validation through large-scale clinical trials. Here, in a randomized, open-label trial, we randomly assigned 802 prediabetic subjects to a usual care control group (patient education and dietary recommendations, n = 393) or a dietary fiber intervention group (n = 409) for 6 months. The primary outcome was the percentage change in whole-blood HbA1c, and secondary outcomes were the changes in other glucose, insulin, lipid, liver and kidney function, and anthropometric parameters. There were no statistically significant differences in the primary and secondary outcomes between groups. In post-hoc analysis, we reclassified subjects into four clusters using a multivariate clustering model based on age, BMI, HbA1c, HOMA2-IR and HOMA2-B. These clusters differed in metabolic status, risks of diabetes and its complications, gut microbiome and serum metabolites. Notably, dietary fiber improved glycemic control in Clusters 3 and 4, but not in Clusters 1 and 2, consistent with observed gut microbiota alleviations. By using a LightGBM machine learning model, we calculated a microbiome-based clinical decision score to predict personalized fiber intervention responses and identified individuals who can get glycemic benefits. In conclusion, our study suggests that the gut microbiota response influences the effectiveness of dietary fiber intervention and provides a clinically applicable model to guide microbiome-targeted personalized medicine for prediabetes. Clinical Trial Registry: ChiCTR1900027663.

> **中文摘要：**
> 肠道微生物群在糖尿病前期的进展中起重要作用，然而，微生物群特征是否能用于指导糖尿病的针对性预防与治疗，仍需通过大规模临床试验加以验证。在本研究中，我们开展了一项随机、开放标签的临床试验，将802例糖尿病前期受试者随机分配至常规护理对照组（患者教育与膳食建议，n = 393）或膳食纤维干预组（n = 409），干预期为6个月。主要结局为全血HbA1c的百分比变化，次要结局包括血糖、胰岛素、血脂、肝肾功能及人体测量等其他指标的变化。结果显示，两组在主要和次要结局上均无统计学显著差异。事后分析中，我们基于年龄、BMI、HbA1c、HOMA2-IR和HOMA2-B等变量，利用多变量聚类模型将受试者重新分为四个亚群。这些亚群在代谢状态、糖尿病及其并发症风险、肠道微生物群组成以及血清代谢物方面存在差异。值得注意的是，膳食纤维在第3组和第4组中改善了血糖控制，而在第1组和第2组中未见此效应，该结果与观察到的肠道微生物群改善趋势一致。通过构建LightGBM机器学习模型，我们计算出基于微生物群的临床决策评分，用以预测个体对膳食纤维干预的反应，并识别出可从中获益的受试者。综上所述，本研究提示肠道微生物群的反应影响膳食纤维干预的效果，并提供了一种可用于指导糖尿病前期微生物组靶向个体化医学的临床应用模型。临床试验注册号：ChiCTR1900027663。

### 第二部分 AI 大师评价

该研究通过随机、开放标签试验评估膳食纤维对糖尿病前期人群血糖控制的影响，并结合肠道微生物组特征探讨个体化反应差异。结果显示总体效果不显著，但在特定代谢亚群中观察到血糖改善，与肠道微生物群的变化一致。作者进一步利用机器学习模型构建了基于微生物群的预测工具，实现了精准营养干预的临床可应用框架。研究的创新性在于将多组学与AI决策模型结合，为糖尿病早期干预提供了新思路，但仍需更大样本和长期随访验证模型的稳健性。

---

## 16. APOBEC3通过IL-1A/AP-1信号通路促进鳞状分化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390483)
**期刊：** Nature communications
**PMID：** 41390483
**DOI：** 10.1038/s41467-025-67033-8

### 第一部分 原文与翻译

**英文原标题：** APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.

> **英文摘要：**
> The APOBEC3 family of RNA and single stranded DNA cytidine deaminases contribute prominently to the mutagenesis of certain cancers including urothelial carcinoma of the bladder (UC). Remarkably, up to 70% of mutations in UC are attributable to the mutagenic activity of the APOBEC3 deaminases. Despite this strong association, few functional studies have investigated APOBEC3's role in bladder cancer. We report a genetically engineered murine model with conditional knock out of Pten and Trp53 in addition to overexpression of mouse Apobec3 (UPPA). Analysis of bladder tumors from UPPA mice demonstrates that mA3 promotes tumor progression and squamous trans-differentiation. We establish that APOBEC3 promotes squamous differentiation through IL-1α and downstream activation of the AP-1 transcription factor. Bulk RNA-sequencing from human UC shows APOBEC3A as the only human APOBEC3 family member to correlate with squamous differentiation. Furthermore, single cell and spatial transcriptomics reinforces the role of APOBEC3A in fostering squamous trans-differentiation and promoting the emergence of a subpopulation of highly squamous epithelial cells. Our results demonstrate that mouse Apobec3 and human APOBEC3A promote squamous differentiation in urothelial carcinoma and that this trans-differentiation phenotype is mediated through IL-1α signaling, a target of FDA approved therapies for rheumatologic disease.

> **中文摘要：**
> APOBEC3家族是一类作用于RNA和单链DNA的胞嘧啶脱氨酶，在包括膀胱尿路上皮癌（UC）在内的某些癌症的突变生成中起主要作用。值得注意的是，在UC中多达70%的突变可归因于APOBEC3脱氨酶的致突变活性。尽管这种关联十分显著，但仍缺乏探究APOBEC3在膀胱癌中功能作用的研究。我们报道了一种基因工程小鼠模型，其中在条件性敲除Pten和Trp53的基础上过表达小鼠Apobec3（UPPA）。对UPPA小鼠膀胱肿瘤的分析表明，mA3可促进肿瘤进展及鳞状转分化。我们证实APOBEC3通过IL-1α及其下游AP-1转录因子的激活促进鳞状分化。人类UC的总体RNA测序结果显示，APOBEC3A是唯一与鳞状分化相关的人类APOBEC3家族成员。此外，单细胞及空间转录组学进一步强化了APOBEC3A在促进鳞状转分化以及形成高鳞状上皮细胞亚群中的作用。我们的结果表明，小鼠Apobec3与人类APOBEC3A均可促进尿路上皮癌中的鳞状分化，这种转分化表型通过IL-1α信号介导，而该信号通路是FDA已批准用于风湿疾病治疗的靶点。

### 第二部分 AI 大师评价

该研究通过构建同时敲除Pten和Trp53并过表达Apobec3的小鼠模型，揭示APOBEC3在促进膀胱尿路上皮癌鳞状分化中的功能作用。作者发现APOBEC3A通过IL-1α信号和下游AP-1转录因子驱动鳞状转分化，且在人类UC中与鳞状表型显著相关。利用整体RNA测序、单细胞及空间转录组学的多层证据强化了该机制的可靠性。该发现不仅拓展了对APOBEC3致突变活性的功能理解，也提示IL-1α通路可能成为膀胱癌分化治疗的新靶点，但仍需进一步验证其临床适用性。

---

## 17. 基于瞬时发光DNA微珠的空间荧光条码

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390472)
**期刊：** Nature communications
**PMID：** 41390472
**DOI：** 10.1038/s41467-025-67410-3

### 第一部分 原文与翻译

**英文原标题：** Spatial fluorescence barcode by transiently luminescent DNA beads.

> **英文摘要：**
> Multiplexed nucleic-acid detection is essential for molecular diagnostics and spatial genomics, but conventional fluorescence methods are often limited by spectral overlap, nonspecific signals, and restricted encoding capacity. We present a spatial fluorescence barcode (SFB) platform based on transiently luminescent DNA beads (TLDBs) that enables single-color, high-plex readout. In this method, targets are encoded through the spatial arrangement of DNA-functionalized beads, eliminating the need for multicolor labeling or spectral unmixing. Target recognition is achieved through toehold-mediated strand displacement, and built-in nucleases enable autonomous enzymatic resetting for repeated use of probes. The system employs monochromatic spatial encoding, decoupling encoding capacity from spectral channels, and features a simplified probe design and decoding workflow. Self-resetting probes not only streamline the encoding process but also enhance practicality by allowing repeated assays without the need to re-prepare costly probe combinations. We demonstrate robust detection of pathogen-derived nucleic acids in infected blood and cancer-associated microRNAs in tissue samples, validating the platform's clinical applicability. Compared to existing barcoding strategies, SFB integrates monochromatic spatial encoding, simplified design, and autonomous reusability, offering a practical, scalable, and cost-effective solution for high-throughput nucleic acid analysis.

> **中文摘要：**
> 多重核酸检测对于分子诊断和空间基因组学至关重要，但传统的荧光方法往往受限于光谱重叠、非特异性信号以及有限的编码能力。我们提出了一种基于瞬时发光DNA微珠（TLDBs）的空间荧光条码（SFB）平台，可实现单色高通量读出。在该方法中，通过DNA功能化微珠的空间排列对目标进行编码，从而无需多色标记或光谱解混。目标识别通过发卡介导的链置换实现，内置的核酸酶可实现探针的自主酶促复位，以便重复使用。该系统采用单色空间编码，将编码容量与光谱通道解耦，并具有简化的探针设计与解码流程。自复位探针不仅简化了编码过程，还通过允许重复检测而无需重新制备昂贵的探针组合，提高了实用性。我们展示了该平台在感染血液中的病原体来源核酸及组织样本中癌症相关微RNA检测中的稳定性能，验证了其临床适用性。与现有的条码策略相比，SFB融合了单色空间编码、简化设计和自主可复用特性，为高通量核酸分析提供了一种实用、可扩展且具成本效益的解决方案。

### 第二部分 AI 大师评价

该研究旨在开发一种基于瞬时发光DNA微珠的空间荧光条码平台，以解决传统荧光检测在光谱重叠与编码容量上的限制。其核心创新在于实现单色高通量编码与自复位探针机制，使核酸检测既可重复使用又减少成本。该方法简化了探针设计和解码流程，展现了优异的多重检测性能。其在病原体与肿瘤相关核酸检测中的验证结果突出了其临床可行性，尽管后续大规模应用仍需在复杂体系中进一步评估稳健性。

---

## 18. 利用基因扰动数据评估体外细胞模型向体内人类表型的可迁移性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390353)
**期刊：** Nature communications
**PMID：** 41390353
**DOI：** 10.1038/s41467-025-67199-1

### 第一部分 原文与翻译

**英文原标题：** Evaluating transportability of in vitro cellular models to in vivo human phenotypes using gene perturbation data.

> **英文摘要：**
> Gene perturbation screens (e.g. CRISPR-Cas9) assess the impact of gene disruption on in-vitro cellular phenotypes (e.g., proliferation, anti-viral response). In-vitro experiments can be useful models for in-vivo (organismal) phenotypes (e.g., immune cell anti-viral response and infectious diseases). However, assessing whether an in-vitro cellular model effectively captures in-vivo biology is challenging. An in-vitro model is 'transportable' to an in-vivo phenotype if perturbations impacting the in-vitro phenotype also impact the in-vivo phenotype with mechanism-consistent directionality and effect sizes. We propose a framework; Gene Perturbation Analysis for Transportability (GPAT), to assess model transportability using gene perturbation effect estimates from perturbation screens (in-vitro) and loss-of-function burden tests (in-vivo). In hypothesis-driven analyses, GPAT provides evidence for model transportability of higher lysosomal cholesterol accumulation in-vitro to lower human plasma LDL-cholesterol (P = 0.0006), consistent with the known role of lysosomes in lipid biosynthesis. In contrast, there was limited evidence for other putative in-vitro models. In hypothesis-free analyses, we find evidence for transportability of cancer cell line proliferation to in-vivo human plasma cellular phenotypes (e.g. erythroleukemia proliferation and plasma lymphocyte percentage). Here we show that perturbation data can be used to evaluate transportability of in-vitro cellular models, informing assay prioritisation and supporting novel hypothesis generation.

> **中文摘要：**
> 基因扰动筛选（例如 CRISPR-Cas9）用于评估基因破坏对体外细胞表型（如增殖、抗病毒反应）的影响。体外实验可作为体内（有机体）表型（如免疫细胞抗病毒反应及感染性疾病）的有用模型。然而，评估体外细胞模型是否能有效反映体内生物学过程是一项挑战。如果影响体外表型的扰动在机制一致的方向性和效应大小上也影响体内表型，则该体外模型可被认为可“迁移”至体内表型。我们提出了一个名为“用于可迁移性评估的基因扰动分析”（Gene Perturbation Analysis for Transportability, GPAT）的框架，通过结合扰动筛选（体外）的基因扰动效应估计与功能缺失负担检验（体内）来评估模型可迁移性。在假设驱动分析中，GPAT 显示体外溶酶体胆固醇积累增加可迁移至人类血浆 LDL-胆固醇降低（P = 0.0006），这与溶酶体在脂质生物合成中的已知作用一致。相比之下，对其他假定的体外模型的证据有限。在无假设分析中，我们发现癌细胞系增殖向体内人类血浆细胞表型（如红白血病细胞增殖和血浆淋巴细胞百分比）具有可迁移性的证据。本研究表明，基因扰动数据可用于评估体外细胞模型的可迁移性，从而指导实验体系优先级选择，并促进新假设的生成。

### 第二部分 AI 大师评价

该研究旨在建立一种用于验证体外细胞模型能否有效代表体内人类表型的量化框架GPAT。作者通过整合基因扰动筛选与体内功能缺失负担分析，系统评估模型的可迁移性。结果显示，溶酶体胆固醇积累与血浆LDL-C呈负相关的可迁移性得到显著验证，而其他模型的支持证据有限。此方法学创新为连接体外实验与人体生理表型提供了可操作路径，但仍需更多异质性数据验证其普适性。

---

## 19. 利用网络基元提升人工神经网络性能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390340)
**期刊：** Nature communications
**PMID：** 41390340
**DOI：** 10.1038/s41467-025-66533-x

### 第一部分 原文与翻译

**英文原标题：** Leveraging network motifs to improve artificial neural networks.

> **英文摘要：**
> As the scale of artificial neural networks continues to expand to tackle increasingly complex tasks or improve the prediction accuracy of specific tasks, the challenges associated with computational demand, hyper-parameter tuning, model interpretability, and deployment costs intensify. Addressing these challenges requires a deeper understanding of how network structures influence network performance. Here, we analyse 882,000 motifs to reveal the functional roles of incoherent and coherent three-node motifs in shaping overall network performance. Our findings reveal that incoherent loops exhibit superior representational capacity and numerical stability, whereas coherent loops show a distinct preference for high-gradient regions within the output landscape. By avoiding such gradient pursuit, incoherent loops sustain more stable adaptation and consequently greater robustness. This mechanism is evident in 97,240 fixed-network training experiments, where coherent-loop networks consistently prioritized high-gradient regions during learning, and is further supported by noise-resilience analyses - from classical reinforcement learning tasks to biological, chemical, and medical applications - which demonstrate that incoherent-loop networks maintain stronger resistance to training noise and environmental perturbations. This work shows the functional impact of structural motif differences on the performance of artificial neural networks, offering foundational insights for designing more resilient and accurate networks.

> **中文摘要：**
> 随着人工神经网络的规模不断扩大，以应对日益复杂的任务或提高特定任务的预测精度，计算需求、超参数调优、模型可解释性及部署成本等相关挑战也随之加剧。要解决这些挑战，需要更深入地理解网络结构如何影响网络性能。在本研究中，我们分析了882,000个网络基元，以揭示非一致和一致三节点基元在塑造整体网络性能中的功能作用。我们的研究发现，非一致环路表现出更优越的表征能力和数值稳定性，而一致环路则对输出景观中的高梯度区域表现出明显偏好。通过避免这种梯度追逐，非一致环路能够维持更稳定的适应过程，从而表现出更强的鲁棒性。这一机制在97,240次固定网络训练实验中得到了证实，其中一致环路网络在学习过程中始终优先关注高梯度区域，并且这一结果进一步得到抗噪分析的支持——从经典的强化学习任务到生物、化学及医学应用——结果显示，非一致环路网络在应对训练噪声和环境扰动方面具有更强的抵抗力。本研究揭示了结构基元差异对人工神经网络性能的功能性影响，为设计更具鲁棒性和精确性的网络提供了基础性见解。

### 第二部分 AI 大师评价

本研究旨在探讨网络结构中不同类型基元对人工神经网络性能的影响。作者通过大规模分析三节点基元，系统揭示了非一致与一致环路在表征能力、数值稳定性及梯度响应模式上的差异。研究通过数万次固定网络实验及多场景抗噪分析验证了非一致环路的鲁棒性优势。该工作将结构生物网络分析理念引入神经网络设计，提出了以网络拓扑特征优化深度学习架构的新思路，其创新性显著，但仍需验证其在更复杂任务和真实部署中的普适性。

---

## 20. Selumetinib 在 1 型神经纤维瘤病成人中的临床获益——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390208)
**期刊：** Lancet (London, England)
**PMID：** 41390208
**DOI：** 10.1016/S0140-6736(25)02248-2

### 第一部分 原文与翻译

**英文原标题：** Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文为作者针对既往报道的 Selumetinib 在 1 型神经纤维瘤病成人患者临床效益的回应信。尽管未提供摘要，推测其主要目的是澄清研究发现、补充数据解释或回应同行质疑。此类作者回复通常聚焦于疗效评估、药物安全性及研究方法学问题，强化了研究结果的可信度与学术讨论的深度。其创新性较低但在学术交流和证据验证中具有重要价值。

---

## 21. 世界卫生组织的分类错误

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390202)
**期刊：** Lancet (London, England)
**PMID：** 41390202
**DOI：** 10.1016/S0140-6736(25)02307-4

### 第一部分 原文与翻译

**英文原标题：** WHO's category mistake.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文题为“世界卫生组织的分类错误”，可能是一篇针对世卫组织在公共卫生政策或疾病分类框架上存在概念性或逻辑性偏差的评论文章。尽管缺乏摘要，但标题暗示作者试图从哲学或制度分析角度审视WHO在某一议题上的认知偏差。此类论述通常以批判性思考为主，旨在推动全球卫生治理的框架反思。文章的学术价值或在于引发关于概念分类及政策执行一致性的再讨论。

---

## 22. CD177中性粒细胞通过促进内皮迁移、细胞外基质降解及HGF-α释放驱动肝再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390175)
**期刊：** Gut
**PMID：** 41390175
**DOI：** 10.1136/gutjnl-2025-336300

### 第一部分 原文与翻译

**英文原标题：** .

> **英文摘要：**
> BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) effectively induces rapid liver hypertrophy in patients with initially unresectable liver tumours, yet the immunological mechanisms remain unclear.
> 
> OBJECTIVE: We aim to elucidate the immune alterations and underlying mechanisms driving liver regeneration following ALPPS.
> 
> DESIGN: The cohort study included single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on remnant liver tissues from ALPPS patients. Neutrophil infiltration was validated by flow cytometry and histological analyses in the world's largest ALPPS clinical cohort and mouse ALPPS models. Functional validation, including neutrophil depletion, matrix metalloproteinase 9 (MMP9) inhibition and CD177 blockade, as well as  knockout and CD177 neutrophil infusion in vivo.
> 
> RESULTS: scRNA-seq revealed substantial neutrophil infiltration following stage 1 ALPPS. Depletion of neutrophils impaired liver regeneration. Among subsets, CD177 neutrophils were metabolically active with enhanced neutrophil extracellular traps formation and secreted MMP9. MMP9 inhibition disrupted extracellular matrix (ECM) degradation and hepatocyte growth factor alpha (HGF-α) release, impairing regeneration. CD177 neutrophils interacted with endothelial cells via CD177-PECAM1 to facilitate transmigration, while hepatic stellate cell-derived CXCL8 promoted neutrophil chemotaxis via CXCL8-CXCR1/2. Cd177 deficiency attenuated neutrophil infiltration and regenerative growth, while CD177 neutrophil infusion restored regeneration, which was abolished in Cd177/ mice.
> 
> CONCLUSIONS: CD177 neutrophils drive liver regeneration by promoting endothelial transmigration, ECM degradation and HGF-α release. These findings reveal a neutrophil-mediated mechanism driving surgical liver regeneration and support the potential of CD177 neutrophil infusion to establish a proregenerative hepatic environment for therapeutic strategies in liver failure.

> **中文摘要：**
> 背景：分期肝切除术（ALPPS，肝分隔联合门静脉结扎术）能有效诱导原本无法切除的肝肿瘤患者出现快速的肝脏肥大，但其免疫学机制仍不清楚。
> 
> 目的：我们旨在阐明ALPPS术后驱动肝再生的免疫变化及其潜在机制。
> 
> 设计：该队列研究在ALPPS患者残余肝组织上开展了单细胞RNA测序（scRNA-seq）及空间转录组分析。通过世界上最大的ALPPS临床队列与小鼠ALPPS模型中的流式细胞术和组织学分析验证中性粒细胞的浸润。功能验证包括中性粒细胞清除、基质金属蛋白酶9（MMP9）抑制及CD177阻断，同时在体内进行了敲除及CD177中性粒细胞输注实验。
> 
> 结果：scRNA-seq显示ALPPS第一阶段后存在大量中性粒细胞浸润。清除中性粒细胞会损害肝再生。在中性粒细胞亚群中，CD177阳性中性粒细胞代谢活跃，具有增强的中性粒细胞胞外诱捕网形成能力并分泌MMP9。MMP9抑制会破坏细胞外基质（ECM）降解及肝细胞生长因子α（HGF-α）的释放，从而削弱肝再生。CD177中性粒细胞通过CD177-PECAM1与内皮细胞相互作用以促进跨内皮迁移，而肝星状细胞来源的CXCL8则通过CXCL8-CXCR1/2促进中性粒细胞趋化。Cd177缺失会减弱中性粒细胞浸润与再生性生长，而CD177中性粒细胞输注可恢复再生，但在Cd177缺失小鼠中该恢复作用消失。
> 
> 结论：CD177中性粒细胞通过促进内皮迁移、细胞外基质降解及HGF-α释放来驱动肝再生。这些发现揭示了一种中性粒细胞介导的手术性肝再生机制，并支持CD177中性粒细胞输注作为建立促再生肝环境、治疗肝功能衰竭的潜在策略。

### 第二部分 AI 大师评价

该研究系统揭示ALPPS术后肝再生的免疫学基础，确定CD177中性粒细胞在促进肝再生中的关键作用。通过scRNA-seq、空间转录组及多层次体内验证，研究清楚描绘了CD177中性粒细胞调控ECM降解及HGF-α释放的机制。其创新性在于结合人群与动物模型，构建了中性粒细胞驱动的手术性肝再生模型。局限性方面，仍需探讨CD177中性粒细胞在其他肝损伤状态下的可推广性及临床安全性。

---

## 23. 通过预防性护理策略降低大型手术后中度或重度急性肾损伤发生率（BigpAK-2）：一项多国随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41242333)
**期刊：** Lancet (London, England)
**PMID：** 41242333
**DOI：** 10.1016/S0140-6736(25)01717-9

### 第一部分 原文与翻译

**英文原标题：** A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.

> **英文摘要：**
> BACKGROUND: Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery.
> 
> METHODS: BigpAK-2 was a multicentre randomised clinical trial done in 34 hospitals in Europe. Patients (aged ≥18 years) undergoing major surgery at high risk for AKI identified by predefined clinical risk factors and tubular stress biomarkers were randomly assigned to usual care or a preventive care strategy as per recommendations by the Kidney Disease Improving Global Outcome guidelines: advanced hemodynamic monitoring, optimisation of volume status and haemodynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia. The primary outcome was the occurrence of moderate or severe AKI within 72 h after surgery, assessed in the intention-to-treat population. Safety was assessed by comparing rates of adverse events between groups. This trial is registered with ClinicalTrials.gov, NCT04647396.
> 
> FINDINGS: From Nov 25, 2020, to June 21, 2024, 7873 patients were screened and 1180 (15·0%) were randomly assigned (589 [49·9%] to the intervention group and 591 [50·1%] to the control group). Among the 1176 patients available for the primary endpoint analysis, moderate or severe AKI occurred in 84 (14·4%) patients in the intervention group and in 131 (22·3%) patients in the control group (odds ratio 0·57 [95% CI 0·40-0·79; p=0·0002; number needed to treat 12 [7-33]). There were no differences in adverse events. The most common adverse events were atrial fibrillation (50 [8·8%] in the intervention group vs 56 (9·7%) in the control group), hemodynamically relevant arrhythmias (41 [7·2%] in the intervention group vs 50 [8·6%] in the control group), significant bleeding or haemorrhage (34 [6·0%] in the intervention group vs 31 [5·3%] in the control group), and unplanned return to the operating room (29 [5·1%] in the intervention vs 38 [6·5%] in the control group).
> 
> INTERPRETATION: Among adults at high risk for AKI undergoing major surgery, a preventive care strategy consisting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of moderate or severe AKI without increasing adverse events.
> 
> FUNDING: BioMérieux.

> **中文摘要：**
> 背景：急性肾损伤（AKI）是大型手术中常见且重要的并发症，然而推荐的预防性护理措施却很少被落实。我们使用尿液生物标志物来识别高风险的AKI患者，并实施了一项预防性护理策略，以减少大型手术后72小时内的AKI发生。
> 
> 方法：BigpAK-2是一项在欧洲34家医院开展的多中心随机临床试验。入组患者为年龄≥18岁的接受重大手术、且根据预定义的临床风险因素和肾小管应激生物标志物识别为AKI高风险者。这些患者被随机分配至常规护理组或依据《肾脏病改善全球预后（KDIGO）》指南推荐的预防性护理策略组。该策略包括：高级血流动力学监测、优化容量状态和血流动力学、避免使用肾毒性药物和放射造影剂，以及预防高血糖。主要结局为术后72小时内发生中度或重度AKI的比例，采用意向性治疗人群进行评估。安全性通过比较两组的不良事件发生率来评估。该试验已在ClinicalTrials.gov注册，编号为NCT04647396。
> 
> 结果：从2020年11月25日至2024年6月21日，共筛查7873名患者，其中1180名（15.0%）被随机分配（干预组589人［49.9%］，对照组591人［50.1%］）。在可用于主要终点分析的1176名患者中，干预组有84人（14.4%）发生中度或重度AKI，而对照组为131人（22.3%）（比值比0.57［95% CI 0.40–0.79；p=0.0002；需治疗人数为12［7–33］）。两组不良事件无显著差异。最常见的不良事件包括心房颤动（干预组50人［8.8%］，对照组56人［9.7%］）、具有血流动力学意义的心律失常（干预组41人［7.2%］，对照组50人［8.6%］）、显著出血或出血事件（干预组34人［6.0%］，对照组31人［5.3%］）以及非计划再次手术（干预组29人［5.1%］，对照组38人［6.5%］）。
> 
> 解释：在接受大型手术且存在AKI高风险的成年人中，由支持性措施及避免肾毒性因素组成的预防性护理策略，能显著降低中度或重度AKI的发生率，而不会增加不良事件风险。
> 
> 资金来源：生物梅里埃公司（BioMérieux）。

### 第二部分 AI 大师评价

本研究是一项多国多中心随机临床试验，通过生物标志物筛选高风险患者并实施KDIGO推荐的综合预防策略，有效降低了大型手术后中重度AKI的发生率。干预措施聚焦于血流动力学优化与避免肾毒性暴露，体现出精准风险识别与机制导向预防的创新思路。结果显示该策略在不增加不良事件的情况下显著改善肾脏预后。其临床价值突出，但未来需评估不同手术类型及长期肾功能的受益持久性。

---

速递结束，祝您工作愉快！